Header Logo
Keywords
Last Name
Institution
Announcement

You can now add alternative names! Click here to add other names that you've published under.
 Back to Details

Connection

Martin Cannon to Immunotherapy

This is a "connection" page, showing publications Martin Cannon has written about Immunotherapy.

 
Connection Strength
  
 
 
1.983
  
  1. Cannon MJ, Block MS, Morehead LC, Knutson KL. The evolving clinical landscape for dendritic cell vaccines and cancer immunotherapy. Immunotherapy. 2019 02; 11(2):75-79.
    View in: PubMed
    Score: 0.565
  2. Chiriva-Internati M, Cobos E, Cannon MJ. Prospects and challenges for immunotherapy of ovarian cancer--what can we learn from the tumor microenvironment? Int Rev Immunol. 2011 Apr-Jun; 30(2-3):67-70.
    View in: PubMed
    Score: 0.328
  3. Chiriva-Internati M, Mirandola L, Kast WM, Jenkins MR, Cobos E, Cannon MJ. Understanding the cross-talk between ovarian tumors and immune cells: mechanisms for effective immunotherapies. Int Rev Immunol. 2011 Apr-Jun; 30(2-3):71-86.
    View in: PubMed
    Score: 0.328
  4. Cannon MJ, Santin AD, O'Brien TJ. Immunological treatment of ovarian cancer. Curr Opin Obstet Gynecol. 2004 Feb; 16(1):87-92.
    View in: PubMed
    Score: 0.200
  5. Cannon MJ, O'Brien TJ, Underwood LJ, Crew MD, Bondurant KL, Santin AD. Novel target antigens for dendritic cell-based immunotherapy against ovarian cancer. Expert Rev Anticancer Ther. 2002 Feb; 2(1):97-105.
    View in: PubMed
    Score: 0.174
  6. Kieber-Emmons T, Pennisi A, Lane A, Siegel E, Cannon M, Monzavi-Karbassi B, Makhoul I. Defining and managing expectations for early immunotherapy cancer trials. Rev Recent Clin Trials. 2015; 10(1):47-60.
    View in: PubMed
    Score: 0.106
  7. Chiriva-Internati M, Mirandola L, Yu Y, Jenkins MR, Gornati R, Bernardini G, Gioia M, Chiaramonte R, Cannon MJ, Kast WM, Cobos E. Cancer testis antigen, ropporin, is a potential target for multiple myeloma immunotherapy. J Immunother. 2011 Jul-Aug; 34(6):490-9.
    View in: PubMed
    Score: 0.083
  8. Pashov A, Monzavi-Karbassi B, Chow M, Cannon M, Kieber-Emmons T. Immune surveillance as a rationale for immunotherapy? Hum Vaccin. 2007 Sep-Oct; 3(5):224-8.
    View in: PubMed
    Score: 0.063
  9. Santin AD, Bellone S, Roman JJ, Burnett A, Cannon MJ, Pecorelli S. Therapeutic vaccines for cervical cancer: dendritic cell-based immunotherapy. Curr Pharm Des. 2005; 11(27):3485-500.
    View in: PubMed
    Score: 0.053
  10. Santin AD, Bellone S, Gokden M, Cannon MJ, Parham GP. Vaccination with HPV-18 E7-pulsed dendritic cells in a patient with metastatic cervical cancer. N Engl J Med. 2002 May 30; 346(22):1752-3.
    View in: PubMed
    Score: 0.044
  11. Chiriva-Internati M, Yu Y, Mirandola L, D'Cunha N, Hardwicke F, Cannon MJ, Cobos E, Kast WM. Identification of AKAP-4 as a new cancer/testis antigen for detection and immunotherapy of prostate cancer. Prostate. 2012 Jan; 72(1):12-23.
    View in: PubMed
    Score: 0.021
  12. Bellone S, Anfossi S, O'Brien TJ, Cannon MJ, Silasi DA, Azodi M, Schwartz PE, Rutherford TJ, Pecorelli S, Santin AD. Generation of CA125-specific cytotoxic T lymphocytes in human leukocyte antigen-A2.1-positive healthy donors and patients with advanced ovarian cancer. Am J Obstet Gynecol. 2009 Jan; 200(1):75.e1-10.
    View in: PubMed
    Score: 0.017
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.